mrna Archives - Page 2 of 4

ReNAgade Therapeutics unveiled new LNPs for delivering mRNA to extra-hepatic tissues: Patent analysis on its proprietary ionizable lipids

Posted on November 6, 2023February 5, 2024 by knowmade

SOPHIA ANTIPOLIS, France – November 06, 2023 │ReNAgadeTherapeutics, a company founded in 2021 and based in Cambridge, presented preclinical data demonstrating a new and proprietary method of delivering mRNA to extra-hepatic tissues in non-human primate using lipid nanoparticles (LNPs) at the 11th International mRNA Health Conference, taking place from October 31 to November 2, 2023[…]

Q3 2023 Therapeutic mRNA patent monitor report: focus on mRNA modifications for an improved efficiency

Posted on October 26, 2023February 5, 2024 by knowmade

SOPHIA ANTIPOLIS, France – October 25, 2023 │ The quarterly report for the Q3 2023 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. Let’s focus on an aspect of mRNA design that that ended up in a Nobel prize! mRNA[…]

Q2 2023 Therapeutic mRNA Patent Monitor Report: LNP still best-in-class delivery & boost for Self-Amplifying mRNA design

Posted on August 31, 2023February 5, 2024 by knowmade

SOPHIA ANTIPOLIS, France – August 31, 2023 │The quarterly report for the Q2 2023 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. Let’s focus on current dynamics in mRNA design. Exploring the dynamic activity of therapeutic mRNA innovations Therapeutic mRNA,[…]

Alnylam kicks off its third round in mRNA delivery battle

Posted on June 6, 2023February 5, 2024 by knowmade

Monitoring litigations in the therapeutic mRNA field SOPHIA ANTIPOLIS, France – June 06, 2023 │ With the COVID-19 crisis, mRNA technologies have become key for numerous players. After the success of mRNA vaccine and the related hype, players are looking to settle their activity and strengthen their position. With this new phase comes litigations. Moderna[…]